bsx072208
On the homepage
NewsBreak
Out There
Local
Tour de France
Boston Sci profit beats expectations, but is off 15%
Print this story
E-mail this story
Save to del.icio.us
Share on Facebook
Share on Digg
Minnesota business by the numbers
See Minnesota's top earning companies, CEOs and non-profits
More from Business
Boston Scientific Corporation's second-quarter net income fell 15 percent amid slumping sales of drug-coated stents.
Profits exceeded analysts' expectations for the struggling medical-device maker, which also offered a rosy third-quarter outlook. Still, shares fell 2.3 percent to $13.48 in after-hours trading.
Boston Scientific -- based in Natick, Mass., with major operations in Maple Grove, Plymouth and Arden Hills -- reported net income of $98 million, or 7 cents a share, down from $115 million, or 8 cents a share, a year earlier. Excluding restructuring, acquisitions and other charges, per-share earnings rose to 20 cents from 16 cents.
Revenue dropped 2.3 percent to $2.02 billion.
The average per-share earnings estimate of analysts polled by Thomson Reuters was 11 cents on revenue of $2.02 billion. Estimates typically exclude one-time charges.
Worldwide sales of drug-coated stents -- tiny metal scaffolds used to prop open blood vessels -- dropped 13 percent, and fell 30 percent in the U.S. alone.
Sales of drug-coated stents have fallen off in the last several quarters as worries about blood clots have given doctors pause about using the devices.
Worldwide sales of heart-rhythm management devices, including implantable cardioverter defibrillators (ICDs), rose 10 percent, while U.S. sales climbed 9.6 percent.
Looking forward, Boston Scientific expects third-quarter per-share earnings of 14 cents to 19 cents on revenue of $1.95 billion to $2.06 billion, compared with Wall Street's view of 12 cents on revenue of $2 billion.
DOW JONES NEWS SERVICE
- GM exits bankruptcy; CEO vows better performance
- Twin Cities advisers accused of fraud, mismanagement
- Oil below $60 as earnings season opens
- Supervalu CEO clears space on executive shelf
- Smith & Hawken to close its doors in Edina
- Mall, teen store sales decline
- AIG, which received $180B in bailouts, asks White House to OK millions in bonuses
Blog: Patent Pending
Farewell VitalMedix
It’s official. VitalMedix Inc., the promising University of Minnesota drug startup, is leaving for Wisconsin. The company, which is developing a hemorrhagic shock drug designed to keep patients alive even after catastrophic blood loss, hasn’t been able to find investors in Minnesota. Wisconsin, on the other hand, boasts a thriving angel investor community thanks to generous [...]
Comment on this story | Be the first to comment | Hide reader comments